drugset
drugset / Trial / NCT04926116

A Study of AK3280 in Chinese Healthy Volunteers

NCT04926116 ↗

Phase 1 Completed 24 enrolled Shanghai Ark Biopharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is a randomized, double-blind, placebo-controlled, single-center, phase I study to evaluate the safety, tolerability, and pharmacokinetics of AK3280 in healthy Chinese subjects.

Timeline

Start
2021-06-09
Primary completion
2021-09-28
Completion
2021-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject AK3280 Unknown 200 mg Oral

Indications

No indication recorded.